Market Summary
USD80.46-0.33
Market Closed-0.41%
MDT Alerts
MDT Stock Price
MDT RSI Chart
MDT Valuation
MDT Price/Sales (Trailing)
MDT Profitability
MDT Fundamentals
MDT Revenue
MDT Earnings
Price Action
52 Week Range
75.1092.02
(Low)(High)
Last 7 days
-1.8%
Last 30 days
-3.9%
Last 90 days
-8.0%
Trailing 12 Months
-5.4%
MDT Financial Health
MDT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for MDT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-23 | Smith Gregory L | sold | -838,400 | 83.84 | -10,000 | evp global ops & supply chain |
2023-08-14 | Wall Brett A. | sold | -83,380 | 83.38 | -1,000 | evp & pres neuroscience |
2023-08-04 | Marinaro Michael | sold | -113,717 | 84.11 | -1,352 | evp & president, surgical ou |
2023-08-03 | Salmon Sean | acquired | - | - | 5,604 | evp & president cardiovascular |
2023-08-03 | Marinaro Michael | acquired | - | - | 1,696 | evp & president, surgical ou |
2023-08-03 | Marinaro Michael | sold (taxes) | -111,780 | 84.49 | -1,323 | evp & president, surgical ou |
2023-08-03 | TEN HOEDT ROB | acquired | - | - | 4,251 | evp and pres. global regions |
2023-08-03 | WHITE ROBERT JOHN | sold (taxes) | -343,452 | 84.49 | -4,065 | evp & pres. medical surgical |
2023-08-03 | Wall Brett A. | acquired | - | - | 5,168 | evp & pres neuroscience |
2023-08-03 | PARKHILL KAREN L | acquired | - | - | 7,105 | evp & chief financial officer |
Which funds bought or sold MDT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | added | 0.96 | 86,341 | 921,967 | 0.78% |
2023-09-14 | Proquility Private Wealth Partners, LLC | added | 0.18 | 315,910 | 3,648,440 | 1.43% |
2023-09-13 | CGC Financial Services, LLC | new | - | 41,759 | 41,759 | 0.03% |
2023-09-12 | DCM Advisors, LLC | unchanged | - | 74,964 | 882,938 | 0.38% |
2023-09-12 | Farther Finance Advisors, LLC | added | 35.86 | 116,457 | 356,765 | 0.08% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | reduced | -3.74 | 1,678 | 34,007 | 0.01% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 2,710,570 | 2,710,570 | 0.14% |
2023-09-05 | Covenant Partners, LLC | added | 30.58 | 117,402 | 392,397 | 0.14% |
2023-09-05 | Westshore Wealth, LLC | reduced | -2.5 | 14,332 | 233,377 | 0.12% |
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | 2,321 | 27,336 | 0.04% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
MDT Alerts
Schedule 13G FIlings of Medtronic
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 15, 2023 | blackrock inc. | 9.2% | 122,349,678 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.41% | 125,126,702 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 8.0% | 107,903,361 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.27% | 111,286,018 | SC 13G/A | |
| Feb 03, 2021 | wellington management group llp | 2.87% | 38,648,749 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.96% | 107,107,760 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 8.55% | 114,617,479 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 8.2% | 109,561,921 | SC 13G/A | |
| Jan 27, 2020 | wellington management group llp | 5.13% | 68,769,139 | SC 13G/A |
Recent SEC filings of Medtronic
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 13, 2023 | ARS | ARS | |
| Aug 31, 2023 | 10-Q | Quarterly Report | |
| Aug 31, 2023 | IRANNOTICE | IRANNOTICE | |
| Aug 25, 2023 | 4 | Insider Trading | |
| Aug 23, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 22, 2023 | 8-K | Current Report | |
| Aug 16, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 11, 2023 | DEFA14A | DEFA14A | |
| Aug 11, 2023 | DEF 14A | DEF 14A |
Peers (Alternatives to Medtronic)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MDT | 107.1B | 31.6B | -3.89% | -5.40% | 29.52 | 3.39 | 1.57% | -30.40% |
ISRG | 99.9B | 6.7B | -0.98% | 45.79% | 70.1 | 14.99 | 11.75% | -0.66% |
EW | 42.7B | 5.7B | -7.62% | -17.65% | 30.7 | 7.54 | 5.64% | -4.53% |
ALGN | 23.0B | 3.7B | -14.60% | 32.47% | 73.17 | 6.15 | -6.33% | -49.26% |
HOLX | 17.3B | 4.0B | -8.83% | 11.42% | 35.74 | 4.28 | -22.73% | -67.98% |
| MID-CAP | ||||||||
PEN | 9.6B | 937.8M | -0.82% | 34.59% | 329.38 | 10.23 | 16.30% | 250.21% |
NVST | 4.5B | 2.6B | -15.10% | -17.76% | 20.82 | 1.75 | 1.78% | -15.77% |
CNMD | 3.1B | 1.1B | -4.32% | 17.29% | 35.22 | 2.73 | 9.28% | 177.49% |
LIVN | 3.0B | 1.1B | 0.89% | 9.63% | -30.91 | 2.77 | 6.60% | -233.50% |
TMDX | 1.9B | 151.1M | -13.07% | 24.15% | -104.73 | 12.31 | 193.70% | 62.80% |
| SMALL-CAP | ||||||||
ESTA | 1.2B | 177.1M | -13.07% | -17.06% | -20.42 | 7.02 | 23.02% | 15.37% |
AVNS | 941.3M | 780.7M | -8.43% | -11.84% | -26.15 | 1.21 | 4.68% | -510.17% |
BLFS | 550.8M | 162.2M | 12.61% | -45.53% | -6.55 | 3.4 | 9.71% | 12.37% |
INGN | 119.4M | 349.3M | -18.77% | -79.39% | -1.24 | 0.34 | -1.13% | -239.54% |
SDC | 53.9M | 414.9M | -23.07% | -60.47% | -0.65 | 0.13 | -23.37% | 16.91% |
Medtronic News
Returns for MDT
Cumulative Returns on MDT
6.1%
10-Year Cumulative Returns
0.7%
7-Year Cumulative Returns
-2.1%
5-Year Cumulative Returns
-7.0%
3-Year Cumulative Returns
Risks for MDT
What is the probability of a big loss on MDT?
53.9%
Probability that Medtronic stock will be more than 20% underwater in next one year
32.7%
Probability that Medtronic stock will be more than 30% underwater in next one year.
0%
Probability that Medtronic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does MDT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Medtronic was unfortunately bought at previous high price.
Drawdowns
Financials for Medtronic
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 1.1% | 31,559 | 31,227 | 30,772 | 30,808 | 31,070 | 31,686 | 31,785 | 31,797 | 31,597 | 30,117 | 27,927 | 27,869 | 27,928 | 28,914 | 31,062 | 30,891 | 30,666 | 30,557 | 30,555 | 30,378 | 29,947 |
| S&GA Expenses | 0.4% | 10,461 | 10,415 | 10,368 | 10,314 | 10,312 | 10,292 | 10,318 | 10,294 | 10,279 | 10,148 | 9,913 | 9,963 | 9,983 | 10,109 | 10,370 | 10,379 | 10,364 | 10,418 | 10,394 | 10,321 | 10,255 |
| EBITDA | -100.0% | - | 8,697 | 8,714 | 8,891 | 9,012 | 8,777 | 8,736 | 8,379 | 7,740 | 7,522 | 6,170 | 6,527 | 6,991 | 7,810 | 9,448 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.28* | 0.28* | 0.29* | 0.29* | 0.28* | 0.27* | 0.26* | 0.24* | 0.25* | 0.22* | 0.23* | 0.25* | 0.27* | 0.30* | - | - | - | - | - | - |
| Interest Expenses | -2.5% | 620 | 636 | 592 | 562 | 580 | 553 | 552 | 558 | 892 | 925 | 946 | 959 | 654 | 1,092 | 1,648 | 1,735 | 1,811 | 1,444 | 1,043 | 1,070 | 1,102 |
| Earnings Before Taxes | 2.9% | 5,517 | 5,364 | 5,416 | 5,630 | 5,728 | 5,517 | 5,481 | 5,112 | 4,144 | 3,895 | 2,534 | 2,893 | 3,662 | 4,055 | 5,142 | 4,933 | 4,994 | 5,197 | 5,630 | 5,287 | 5,660 |
| EBT Margin | -100.0% | - | 0.17* | 0.18* | 0.18* | 0.18* | 0.17* | 0.17* | 0.16* | 0.13* | 0.13* | 0.09* | 0.10* | 0.13* | 0.14* | 0.17* | - | - | - | - | - | - |
| Net Income | -3.5% | 3,627 | 3,758 | 4,071 | 4,329 | 5,211 | 5,039 | 4,926 | 4,716 | 3,893 | 3,606 | 2,901 | 3,546 | 4,423 | 4,809 | 5,335 | 4,689 | 4,433 | 4,631 | 4,919 | 2,261 | 3,163 |
| Net Income Margin | -100.0% | - | 0.12* | 0.13* | 0.14* | 0.17* | 0.16* | 0.15* | 0.15* | 0.12* | 0.12* | 0.10* | 0.13* | 0.16* | 0.17* | 0.17* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 4,580 | 4,166 | 4,822 | 5,721 | 5,978 | 5,678 | 5,773 | 5,855 | 4,885 | 4,631 | 4,752 | 4,756 | 6,021 | 6,659 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -0.2% | 90,776 | 90,948 | 94,134 | 93,241 | 89,914 | 90,981 | 91,804 | 91,756 | 91,802 | 93,083 | 97,270 | 95,886 | 93,906 | 90,689 | 92,822 | 91,053 | 91,268 | 89,694 | 88,730 | 88,150 | 89,721 |
| Current Assets | 0.9% | 21,869 | 21,675 | 25,364 | 25,398 | 22,135 | 23,059 | 23,303 | 22,731 | 22,434 | 22,548 | 26,347 | 26,036 | 24,509 | 22,031 | 24,043 | 22,653 | 22,705 | 21,967 | 20,877 | 21,653 | 22,460 |
| Cash Equivalents | -13.2% | 1,339 | 1,543 | 4,521 | 4,828 | 2,140 | 3,714 | 3,479 | 2,900 | 3,004 | 3,593 | 5,077 | 6,420 | 6,499 | 4,140 | 3,709 | 3,962 | 5,080 | 4,393 | 3,703 | 3,911 | 4,380 |
| Inventory | 7.1% | 5,668 | 5,293 | 5,375 | 5,055 | 4,809 | 4,616 | 4,514 | 4,349 | 4,288 | 4,313 | 4,508 | 4,484 | 4,551 | 4,229 | 4,122 | 4,042 | 3,932 | 3,753 | 3,866 | 3,763 | 3,681 |
| Net PPE | 1.7% | 5,665 | 5,569 | 5,437 | 5,298 | 5,281 | 5,413 | 5,251 | 5,188 | 5,162 | 5,221 | 5,023 | 4,938 | 4,882 | 4,828 | 4,764 | 4,756 | 4,711 | 4,675 | 4,593 | 4,536 | 4,524 |
| Goodwill | 0.0% | 41,436 | 41,425 | 41,565 | 40,417 | 66.00 | 615 | 80.00 | 80.00 | 41,720 | 41,961 | 805 | 381 | 40,714 | 39,841 | 92.00 | 92.00 | 65.00 | 39,959 | 146 | 60.00 | 62.00 |
| Liabilities | 0.3% | 39,410 | 39,283 | 42,516 | 41,184 | 37,071 | 38,260 | 39,091 | 39,596 | 40,137 | 41,481 | 46,342 | 45,570 | 43,463 | 39,817 | 40,869 | 40,334 | 40,771 | 39,482 | 38,789 | 38,436 | 39,392 |
| Current Liabilities | 0.0% | 9,047 | 9,051 | 14,422 | 14,465 | 14,049 | 12,394 | 8,927 | 7,803 | 7,764 | 8,509 | 12,534 | 12,071 | 13,086 | 10,366 | 8,735 | 8,170 | 8,518 | 8,472 | 8,853 | 8,463 | 9,112 |
| Long Term Debt | 0.5% | 24,463 | 24,344 | 22,210 | 20,753 | 17,481 | 20,372 | 24,290 | 25,607 | 25,958 | 26,378 | 26,502 | 25,967 | 22,867 | 22,021 | 24,732 | 24,752 | 24,804 | 24,486 | 23,674 | 23,673 | 23,678 |
| Shareholder's Equity | -0.6% | 51,178 | 51,483 | 51,441 | 52,057 | 52,843 | 52,722 | 52,713 | 52,159 | 51,664 | 51,602 | 50,928 | 50,316 | 50,443 | 50,872 | 51,953 | 50,719 | 50,497 | 50,212 | 49,941 | 49,714 | 50,329 |
| Retained Earnings | -0.4% | 30,265 | 30,392 | 30,117 | 29,799 | 30,276 | 30,250 | 29,607 | 28,974 | 28,511 | 28,594 | 28,015 | 27,526 | 27,817 | 28,132 | 28,210 | 27,018 | 26,377 | 26,270 | 25,769 | 25,171 | 24,730 |
| Additional Paid-In Capital | 0.0% | 24,587 | 24,590 | 24,513 | 24,442 | 24,335 | 24,566 | 25,814 | 26,059 | 26,184 | 26,319 | 26,665 | 26,481 | 26,261 | 26,165 | 26,144 | 26,171 | 26,470 | 26,532 | 26,518 | 27,048 | 27,817 |
| Accumulated Depreciation | - | - | - | 8,489 | 8,199 | 8,043 | 7,952 | 7,823 | 7,790 | 7,646 | 7,479 | 7,375 | 7,260 | 7,070 | 6,816 | 6,743 | 6,608 | 6,425 | 6,245 | 6,153 | 5,976 | 5,812 |
| Shares Outstanding | 0.0% | 1,330 | 1,331 | 1,330 | 1,330 | 1,329 | 1,331 | 1,344 | 1,345 | 1,345 | 1,345 | 1,346 | 1,344 | 1,342 | 1,341 | 1,341 | 1,341 | 1,341 | 1,341 | 1,343 | 1,349 | 1,353 |
| Minority Interest | 3.3% | 188 | 182 | 177 | 177 | 170 | 171 | 171 | 168 | 178 | 174 | 170 | 152 | 147 | 135 | 145 | 141 | 134 | 121 | 112 | 107 | 105 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -3.4% | 5,831 | 6,039 | 5,636 | 6,290 | 7,137 | 7,346 | 7,034 | 7,162 | 7,254 | 6,240 | 5,945 | 5,996 | 6,002 | 7,234 | 7,871 | 7,519 | 6,815 | 7,007 | 5,958 | 5,905 | 5,649 |
| Share Based Compensation | 3.1% | 366 | 355 | 352 | 349 | 352 | 359 | 356 | 343 | 343 | 344 | 337 | 338 | 306 | 297 | 297 | 291 | 287 | 290 | 302 | 314 | 316 |
| Cashflow From Investing | 29.9% | -2,447 | -3,493 | -2,747 | -2,897 | -2,460 | -1,659 | -11.00 | -2,347 | -3,658 | -2,866 | -4,420 | -3,448 | -2,644 | -3,203 | -4,097 | -3,305 | -1,968 | -774 | -134 | 497 | 6,418 |
| Cashflow From Financing | 9.1% | -4,511 | -4,960 | -2,019 | -1,062 | -5,231 | -5,336 | -8,516 | -8,337 | -7,150 | -4,136 | -317 | -192 | -1,965 | -4,198 | -3,748 | -4,143 | -4,132 | -5,431 | -8,399 | -7,980 | -12,386 |
| Dividend Payments | 0.4% | 3,631 | 3,616 | 3,554 | 3,497 | 3,440 | 3,383 | 3,321 | 3,255 | 3,188 | 3,120 | 3,063 | 3,005 | 2,948 | 2,894 | 2,841 | 2,789 | 2,740 | 2,693 | 2,646 | 2,598 | 2,546 |
| Buy Backs | -38.4% | 397 | 645 | 1,890 | 2,199 | 2,472 | 2,544 | 1,616 | 1,253 | 963 | 652 | 195 | 422 | 906 | 1,326 | 1,265 | 1,701 | 2,320 | 2,877 | 2,870 | 2,274 | 1,758 |
MDT Income Statement
2023-07-28Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
|---|---|---|
Jul. 28, 2023 | Jul. 29, 2022 | |
| Income Statement [Abstract] | ||
| Net sales | $ 7,702 | $ 7,371 |
| Costs and expenses: | ||
| Cost of products sold, excluding amortization of intangible assets | 2,628 | 2,516 |
| Research and development expense | 668 | 692 |
| Selling, general, and administrative expense | 2,613 | 2,567 |
| Amortization of intangible assets | 429 | 423 |
| Restructuring charges, net | 54 | 14 |
| Certain litigation charges | 40 | 0 |
| Other operating expense, net | 1 | 35 |
| Operating profit | 1,268 | 1,125 |
| Other non-operating income, net | (76) | (83) |
| Interest expense, net | 148 | 164 |
| Income before income taxes | 1,196 | 1,044 |
| Income tax provision | 400 | 112 |
| Net income | 797 | 931 |
| Net income attributable to noncontrolling interests | (6) | (2) |
| Net income attributable to Medtronic | $ 791 | $ 929 |
| Basic earnings per share (usd per share) | $ 0.59 | $ 0.70 |
| Diluted earnings per share (usd per share) | $ 0.59 | $ 0.70 |
| Basic weighted average shares outstanding (shares) | 1,330.5 | 1,329.4 |
| Diluted weighted average shares outstanding (shares) | 1,333.8 | 1,334.5 |
MDT Balance Sheet
2023-07-28Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jul. 28, 2023 | Apr. 28, 2023 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,339 | $ 1,543 |
| Investments | 6,537 | 6,416 |
| Accounts receivable, less allowances and credit losses of $190 and $176, respectively | 5,806 | 5,998 |
| Inventories, net | 5,668 | 5,293 |
| Other current assets | 2,518 | 2,425 |
| Total current assets | 21,869 | 21,675 |
| Property, plant, and equipment, net | 5,665 | 5,569 |
| Goodwill | 41,436 | 41,425 |
| Other intangible assets, net | 14,434 | 14,844 |
| Tax assets | 3,461 | 3,477 |
| Other assets | 3,912 | 3,959 |
| Total assets | 90,776 | 90,948 |
| Current liabilities: | ||
| Current debt obligations | 519 | 20 |
| Accounts payable | 2,239 | 2,662 |
| Accrued compensation | 1,695 | 1,949 |
| Accrued income taxes | 1,013 | 840 |
| Other accrued expenses | 3,581 | 3,581 |
| Total current liabilities | 9,047 | 9,051 |
| Long-term debt | 24,463 | 24,344 |
| Accrued compensation and retirement benefits | 1,092 | 1,093 |
| Accrued income taxes | 2,407 | 2,360 |
| Deferred tax liabilities | 687 | 708 |
| Other liabilities | 1,715 | 1,727 |
| Total liabilities | 39,410 | 39,283 |
| Commitments and contingencies (Note 16) | ||
| Shareholders’ equity: | ||
| Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,498,304 and 1,330,809,036 shares issued and outstanding, respectively | 0 | 0 |
| Additional paid-in capital | 24,587 | 24,590 |
| Retained earnings | 30,265 | 30,392 |
| Accumulated other comprehensive loss | (3,674) | (3,499) |
| Total shareholders’ equity | 51,178 | 51,483 |
| Noncontrolling interests | 188 | 182 |
| Total equity | 51,366 | 51,665 |
| Total liabilities and equity | $ 90,776 | $ 90,948 |
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.